Company intelligence / Profile preview
Myeloid Therapeutics
Cambridge, MA, USmyeloidtx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Myeloid develops mRNA-immunotherapies combining LNP delivery with CAR engineering to activate myeloid cells against solid tumors. Clinical programs include MT-101 (anti-CD5 CAR) in PTCL and MT-302 (anti-TROP2 CAR) in epithelial cancers, with Fast Track designation received for MT-101.
- Therapeutic areas
- OncologyImmunology
- Modalities
- mRNA-based immunotherapiesCAR-T cell therapiesRNA-based gene editing
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
03
Partnerships
PRIME MedicineAcuitas TherapeuticsNew South Wales Government
Beyond the preview
Go deeper on Myeloid Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myeloid Therapeutics.